Targeting Breast Cancer Stem Cells by Dendritic Cell Vaccination in Humanized Mice with Breast Tumor: Preliminary Results

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2016 Aug 9

PMID 27499638

Citations 20

Authors

Phuc Van Pham

Hanh Thi Le

Binh Thanh Vu

Viet Quoc Pham

Phong Minh Le

Nhan Lu-Chinh Phan

Ngu Van Trinh

Huyen Thi-Lam Nguyen

Sinh Truong Nguyen

Toan Linh Nguyen

Ngoc Kim Phan

Affiliations

Soon will be listed here.

Abstract

Background: Breast cancer (BC) is one of the leading cancers in women. Recent progress has enabled BC to be cured with high efficiency. However, late detection or metastatic disease often renders the disease untreatable. Additionally, relapse is the main cause of death in BC patients. Breast cancer stem cells (BCSCs) are considered to cause the development of BC and are thought to be responsible for metastasis and relapse. This study aimed to target BCSCs using dendritic cells (DCs) to treat tumor-bearing humanized mice models.

Materials And Methods: NOD/SCID mice were used to produce the humanized mice by transplantation of human hematopoietic stem cells. Human BCSCs were injected into the mammary fat pad to produce BC humanized mice. Both hematopoietic stem cells and DCs were isolated from the human umbilical cord blood, and immature DCs were produced from cultured mononuclear cells. DCs were matured by BCSC-derived antigen incubation for 48 hours. Mature DCs were vaccinated to BC humanized mice with a dose of 10(6) cells/mice, and the survival percentage was monitored in both treated and untreated groups.

Results: The results showed that DC vaccination could target BCSCs and reduce the tumor size and prolong survival.

Conclusion: These results suggested that targeting BCSCs with DCs is a promising therapy for BC.

Citing Articles

Integrating immunotherapy with conventional treatment regime for breast cancer patients- an amalgamation of armamentarium.

Nandi D, Sharma D Front Immunol. 2024; 15:1477980.

PMID: 39555066 PMC: 11563812. DOI: 10.3389/fimmu.2024.1477980.

Immunotherapeutic Strategies Targeting Breast Cancer Stem Cells.

Vasileiou M, Diamantoudis S, Tsianava C, Nguyen N Curr Oncol. 2024; 31(6):3040-3063.

PMID: 38920716 PMC: 11203270. DOI: 10.3390/curroncol31060232.

Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies.

Ali K, Nabeel M, Mohsin F, Iqtedar M, Islam M, Rasool M Med Oncol. 2024; 41(5):112.

PMID: 38592510 DOI: 10.1007/s12032-024-02347-z.

Proteomes from AMPK-inhibited peripheral blood mononuclear cells suppress the progression of breast cancer and bone metastasis.

Li K, Sun X, Minami K, Tamari K, Ogawa K, Li H Theranostics. 2023; 13(4):1247-1263.

PMID: 36923539 PMC: 10008730. DOI: 10.7150/thno.80294.

PI3K-activated MSC proteomes inhibit mammary tumors via Hsp90ab1 and Myh9.

Sun X, Li K, Aryal U, Li B, Yokota H Mol Ther Oncolytics. 2022; 26:360-371.

PMID: 36090473 PMC: 9420348. DOI: 10.1016/j.omto.2022.08.003.

References

Pham P, Phan N, Nguyen N, Truong N, Duong T, Le D . Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy. J Transl Med. 2011; 9:209. PMC: 3251542. DOI: 10.1186/1479-5876-9-209. View

Baek S, Kim C, Kim S, Kim Y, Kwon S, Kim Y . Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial. J Transl Med. 2011; 9:178. PMC: 3213212. DOI: 10.1186/1479-5876-9-178. View

Zheng K, Tan J, Wu W, Qiu Y, Zhang H, Xu T . Adjuvant dendritic cells vaccine combined with cytokine-induced-killer cell therapy after renal cell carcinoma surgery. J BUON. 2015; 20(2):505-13. View

Berzofsky J, Terabe M, Oh S, Belyakov I, Ahlers J, Janik J . Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest. 2004; 113(11):1515-25. PMC: 419494. DOI: 10.1172/JCI21926. View

Phuc P, Nhung T, Loan D, Chung D, Ngoc P . Differentiating of banked human umbilical cord blood-derived mesenchymal stem cells into insulin-secreting cells. In Vitro Cell Dev Biol Anim. 2010; 47(1):54-63. DOI: 10.1007/s11626-010-9356-5. View

Mao Q, Li L, Zhang C, Sun Y, Liu S, Cui S . Clinical effects of immunotherapy of DC-CIK combined with chemotherapy in treating patients with metastatic breast cancer. Pak J Pharm Sci. 2015; 28(3 Suppl):1055-8. View

Wilgenhof S, Corthals J, Van Nuffel A, Benteyn D, Heirman C, Bonehill A . Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases. Cancer Immunol Immunother. 2014; 64(3):381-8. PMC: 11029539. DOI: 10.1007/s00262-014-1642-8. View

Van Pham P, Nguyen N, Nguyen H, Tan Khuat L, Le P, Pham V . A simple in vitro method for evaluating dendritic cell-based vaccinations. Onco Targets Ther. 2014; 7:1455-64. PMC: 4145728. DOI: 10.2147/OTT.S67057. View

Singh M, Singh P, Gaudray G, Musumeci L, Thielen C, Vaira D . An improved protocol for efficient engraftment in NOD/LTSZ-SCIDIL-2Rγnull mice allows HIV replication and development of anti-HIV immune responses. PLoS One. 2012; 7(6):e38491. PMC: 3366932. DOI: 10.1371/journal.pone.0038491. View

10.

Khattak M, Fisher R, Turajlic S, Larkin J . Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm. Ther Adv Med Oncol. 2013; 5(2):105-18. PMC: 3556874. DOI: 10.1177/1758834012466280. View

11.

Ma Y, Shurin G, Peiyuan Z, Shurin M . Dendritic cells in the cancer microenvironment. J Cancer. 2013; 4(1):36-44. PMC: 3564245. DOI: 10.7150/jca.5046. View

12.

Nencioni A, Grunebach F, Schmidt S, Muller M, Boy D, Patrone F . The use of dendritic cells in cancer immunotherapy. Crit Rev Oncol Hematol. 2007; 65(3):191-9. DOI: 10.1016/j.critrevonc.2007.10.002. View

13.

Sharma B, Singh R . Emerging candidates in breast cancer stem cell maintenance, therapy resistance and relapse. J Carcinog. 2012; 10:36. PMC: 3263158. DOI: 10.4103/1477-3163.91119. View

14.

Anguille S, Smits E, Lion E, Van Tendeloo V, Berneman Z . Clinical use of dendritic cells for cancer therapy. Lancet Oncol. 2014; 15(7):e257-67. DOI: 10.1016/S1470-2045(13)70585-0. View

15.

Zhan H, Gao X, Pu X, Li W, Li Z, Zhou X . A randomized controlled trial of postoperative tumor lysate-pulsed dendritic cells and cytokine-induced killer cells immunotherapy in patients with localized and locally advanced renal cell carcinoma. Chin Med J (Engl). 2012; 125(21):3771-7. View

16.

Satthaporn S, Robins A, Vassanasiri W, El-Sheemy M, Jibril J, Clark D . Dendritic cells are dysfunctional in patients with operable breast cancer. Cancer Immunol Immunother. 2004; 53(6):510-8. PMC: 11032822. DOI: 10.1007/s00262-003-0485-5. View

17.

Cho D, Yang W, Lee H, Hsu D, Lin H, Lin S . Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial. World Neurosurg. 2011; 77(5-6):736-44. DOI: 10.1016/j.wneu.2011.08.020. View

18.

Van Pham P, Vu N, Duong T, Nguyen T, Truong N, Phan N . Suppression of human breast tumors in NOD/SCID mice by CD44 shRNA gene therapy combined with doxorubicin treatment. Onco Targets Ther. 2012; 5:77-84. PMC: 3358118. DOI: 10.2147/OTT.S30609. View

19.

Hayakawa J, Hsieh M, Uchida N, Phang O, Tisdale J . Busulfan produces efficient human cell engraftment in NOD/LtSz-Scid IL2Rgamma(null) mice. Stem Cells. 2008; 27(1):175-82. PMC: 2696310. DOI: 10.1634/stemcells.2008-0583. View

20.

Banchereau J, Schuler-Thurner B, Palucka A, Schuler G . Dendritic cells as vectors for therapy. Cell. 2001; 106(3):271-4. DOI: 10.1016/s0092-8674(01)00448-2. View